Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

Acrp Presentation Jan 2009

477 Aufrufe

Veröffentlicht am

Veröffentlicht in: Business, Gesundheit & Medizin
  • Hi there! Get Your Professional Job-Winning Resume Here - Check our website! http://bit.ly/resumpro
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier
  • Gehören Sie zu den Ersten, denen das gefällt!

Acrp Presentation Jan 2009

  1. 1. Bridging the Gap and Building Partnerships Between Academia and Industry Industry Perspective
  2. 2. Academic Allure <ul><li>Why Industry works with Academic Institutions: </li></ul><ul><li>Premier scientific and clinical knowledge </li></ul><ul><li>Access to specialized patient populations </li></ul><ul><ul><li>CTCL, organ transplant </li></ul></ul><ul><li>Scientific -> Clinical evaluation of early compounds </li></ul><ul><li>Clinical feasibility assessment during protocol development </li></ul><ul><ul><li>Clinical purpose vs regulatory purpose – frequently not the same </li></ul></ul><ul><li>Credibility through association with reputable institutions and key opinion leaders </li></ul><ul><li>Reputation for authoring publications </li></ul>
  3. 3. Industry Dowry <ul><li>What Industry brings to the relationship: </li></ul><ul><li>70% of clinical research funding comes from Industry </li></ul><ul><ul><li>2008 Global clinical research business = $50B </li></ul></ul><ul><li>Cultivate access to new medicines/treatments/diagnostics </li></ul><ul><li>Clinical trial design and data analysis </li></ul><ul><ul><li>Rigorous data collection </li></ul></ul><ul><li>Regulatory Authority knowledge </li></ul><ul><ul><li>Develops regulatory strategies </li></ul></ul><ul><ul><li>Understands regulations and requirements </li></ul></ul><ul><li>Regulatory capabilities </li></ul><ul><ul><li>Submission preparation </li></ul></ul>
  4. 4. Industry Business Model <ul><li>Even before the current financial crisis, industry has been focused on building efficiencies </li></ul><ul><li>Reduced sales and marketing costs </li></ul><ul><li>Moving trials overseas </li></ul><ul><li>General & Administrative costs – cut to the bone </li></ul><ul><li>Last frontier for cutting costs….. </li></ul><ul><ul><li>Research and Development </li></ul></ul>
  5. 5. Even the Government… <ul><li>“ The clinical research enterprise needs to evolve. It needs to be much more streamlined and efficient.” – Janet Woodcock, FDA Deputy Commissioner, 2008 </li></ul><ul><li>Clinical Trials Transformation Initiative </li></ul>
  6. 6. Challenges for Biotech/Pharma <ul><li>Competition for and access to academic institutions and investigators </li></ul><ul><li>Forced to operate within and accommodate academic confines </li></ul><ul><ul><li>Inflexible and inconsistent systems within and between institutions </li></ul></ul><ul><ul><li>Difficulty integrating processes or equipment to meet study requirements (e.g., software) </li></ul></ul><ul><li>Beholden to shareholders </li></ul><ul><ul><li>Balance high quality with cost-effectiveness </li></ul></ul><ul><ul><li>Time to market </li></ul></ul><ul><ul><li>Pressure to get products on the market - Revenue </li></ul></ul>
  7. 7. Challenges for Industry <ul><li>How the relationship generally begins - Time to Study Start </li></ul><ul><ul><li>Institutional Bureaucracy </li></ul></ul><ul><ul><ul><li>Does the investigator know how to navigate the system? </li></ul></ul></ul><ul><ul><ul><li>Scientific review boards </li></ul></ul></ul><ul><ul><ul><li>Align institutional bureaucracy with industry bureaucracy (hurry up and wait) </li></ul></ul></ul><ul><ul><li>Contract Issues </li></ul></ul><ul><ul><ul><li>Individual contract negotiations, whose contract do you use? </li></ul></ul></ul><ul><ul><ul><li>Significant delays in legal review </li></ul></ul></ul><ul><ul><ul><li>Intellectual property (data ownership) and publication rights </li></ul></ul></ul><ul><ul><ul><li>Payment schedules and milestone establishment </li></ul></ul></ul><ul><ul><li>Budget delays and expense </li></ul></ul><ul><ul><ul><li>Navigating multiple departments to collect budget data </li></ul></ul></ul><ul><ul><ul><li>Higher cost for procedures </li></ul></ul></ul><ul><ul><ul><li>Institutional overhead </li></ul></ul></ul><ul><ul><li>Local IRB </li></ul></ul><ul><ul><ul><li>Application gridlock </li></ul></ul></ul><ul><ul><ul><li>Delays in time to obtain IRB approval (summers, holidays) </li></ul></ul></ul><ul><ul><li>All of this work required if there is one subject enrolled or 100 subjects enrolled </li></ul></ul>
  8. 8. Some room for improvement <ul><li>Industry can bridge the gaps: </li></ul><ul><li>Establish Master Service Agreements with partner institutions and be consistent in their use </li></ul><ul><li>Set realistic project duration dates to accommodate study start up time </li></ul><ul><li>Budget – understanding academic funding needs </li></ul><ul><ul><li>Study start up fees and payment process </li></ul></ul><ul><li>Customized training, give sites tools (checklists) to make their jobs easier, not always a one size fits all mentality </li></ul><ul><li>Develop relationships with key stakeholders / departments within the institution (beyond the investigator) </li></ul><ul><ul><li>Contracts and accounting </li></ul></ul><ul><ul><li>Find a champion at the site </li></ul></ul>
  9. 9. Heather Snyder, PhD Executive Director Ext. 304 Catherine Martin, MD Principal Investigator Department of Psychiatry UKY College of Medicine 3470 Blazer Parkway Lexington, KY 40536 (P): 859-257-9341 (F): 859 -257-3898 [email_address] John Ranseen, PhD Co-Investigator [email_address] Greg Guenther Assistant to Dr. Martin (P): 859-257-9362 [email_address] Bryan D. Beck, MS, LPCC Research Assistant (C): 859-967-4048 (P): 859-323-5824 (F): 859-257-3898 [email_address] Stephen C. Sitzlar, RPh, PharmD Manager, Investigation Drug Service Department of Pharmacy UKY College of Medicine (P): 859-323-2894 (F): 859-323-4765 [email_address] John Hajner Sponsored Projects Administration Kinkaid Hall, Room 114 Lexington, KY 40506-0057 (P): 859-257-4526 [email_address] Sharon Walsh, PhD Consultant Dept. of Behavioral Science University of Kentucky (P): 859-257-6485 [email_address] Laura D’Alonzo Clinical Trial Support Specialist Ext. 324 Alan Smith Statistical Consultant (C): 908-723-0474 (P): 908-879-6168 [email_address] Thomas Laughren, MD Nicholette Hemmingway FDA, CDER Division of Psychiatry Products IND # 100,962 (P): 301-796-9838 Mark Walters Grants Management Specialist Margaret Grabb Program Official NIMH Grant #1R43MH081553-01 Mark Kleven, PhD PI on NIMH Grant Ext. 316 Paul A. Nuzzo Center for Human Behavioral Science Robert Straus Building 515 Oldham Court, Suite 110 Lexington, KY 40502 (P): 859-323-0002 (F): 859-257-5232 [email_address] Yaupon ACI UKY FDA/NIMH
  10. 10. Compromises What can Industry do? What would Industry like to see? <ul><li>Eliminate as many protocol challenges as possible </li></ul><ul><li>Set reasonable timelines </li></ul><ul><li>Develop better personal relationships with key stakeholders at the site </li></ul><ul><li>Elicit continuous feedback from the sites and make accommodations where possible </li></ul><ul><li>Pay invoices on time </li></ul><ul><li>Communicate </li></ul><ul><li>Easier navigation through the institution </li></ul><ul><li>Stronger commitments to timelines </li></ul><ul><li>Refunds for low to no enrollment </li></ul>
  11. 11. References <ul><li>Global Clinical Trial Business Report and Analysis 2008-2018 </li></ul><ul><li>Mello et al, “Academic Medical Centers’ Standards for Clinical Trial Agreements with Industry” NEJM, May 26, 2005 </li></ul><ul><li>Yamada “Academia-industry collaboration: A dynamic partnership on behalf of patients”, presentation to Assoc. of Amer. Phys. 2005 </li></ul>